Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Women treated with hormone-blocking drugs to stave off breast cancer recurrences are often dissatisfied with their sex lives, a new study from Sweden has found.
(Reuters) - The American Civil Liberties Union has asked for a second time that the Supreme Court invalidate Myriad Genetics Inc's patents on two genes associated with hereditary breast and ovarian cancers, the latest salvo in a case with broad consequences for the future of gene-based medicine.
NEW YORK (Reuters Health) - Having an MRI scan before breast cancer surgery may not cut a woman's risk of needing a second operation to go after additional tumor tissue - and may even raise her chance of getting an unnecessary mastectomy, a new study suggests.
NEW YORK (Reuters Health) - The number of pregnant women diagnosed with cancer has increased over the past couple of decades, a new study from Australia suggests.
A study conducted by researchers from the National Cancer Institute, part of the National Institutes of Health, found that high mammographic density in women with breast cancer was not associated with an increased risk of death from the disease.
In a study published in The New England Journal of Medicine, researchers suggest that anastrozole (Arimidex), taken in combination with fulvestrant (Faslodex), extends both progression-free and overall survival in hormone receptor-positive metastatic breast cancer.
LONDON (Reuters) - National breast screening programs in Europe save more lives by catching tumors early than they harm through over-diagnosis and women should be made more aware of that benefit-risk balance, researchers said on Thursday.
A final data analysis of the study EGF104900, which compared lapatinib (Tykerb) plus trastuzumab (Herceptin) to lapatinib alone, found the combination therapy resulted in a significant increase in overall survival in women with HER2 positive metastatic breast cancer.
A new report indicates that the use of bevacizumab (Avastin) in the treatment of women with metastatic breast cancer slows the progression of the disease but has no impact on their overall survival, the length of time women live after receiving treatment, or on their quality of life.
NEW YORK (Reuters Health) - Among women who have been treated for breast cancer, heavier women are more likely to have their disease come back and more likely to die of cancer, according to a new study.